[A18-46] Fluticasone furoate/umeclidinium/vilanterol (COPD) – Addendum to Commission A18-15
Last updated 16.08.2018
Project no.:
A18-46
Commission:
Commission awarded on 09.07.2018 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Airways and respiratory system
Adults with moderate to severe COPD who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta 2 agonist
Conclusion of dossier assessment A18-15 unchanged
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A18-15 | Fluticasone furoate/umeclidinium/vilanterol (COPD) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2018-08-16 A G-BA decision was published.